Rheumatoid Arthritis and Related Disorders

  • Mark B. Stephens
  • William R. Gilliland
Living reference work entry


Joint pain is a common complaint in primary care. Pain can be considered acute (days), subacute (weeks), or chronic (generally lasting more than 6 weeks). Accurately diagnosing the cause of joint pain, encouraging continuity of care, and working with multidisciplinary teams using the right blend of therapeutic modalities gives patients the best chance for good long-term outcomes. This chapter will focus, in particular, on diseases that commonly present with joint pain.


Rheumatoid Arthritis Systemic Lupus Erythematosus Ankylose Spondylitis Juvenile Idiopathic Arthritis Psoriatic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43(7):906–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Ahlmén M, Svensson B, Albertsson K, Forslind K, Hafström I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis. 2010;69(1):230–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1995–2007. Arthritis Rheum. 2010;62(6):1576–82.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Kelly C, Hamilton J. What kills patients with rheumatoid arthritis? Rheumatology. 2007;46(2):183–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Fuller-Thomson E, Liddycoat JP, Stefanyk M. The association between a history of parental addictions and arthritis in adulthood: findings from a representative community survey. Int J Popul Res. 2014. doi:10.1155/2014/582508.Google Scholar
  6. 6.
    Barton A, Worthington J. Genetic susceptibility to rheumatoid arthritis: an emerging picture. Arthritis Rheum. 2009;61(10):1441–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Q J Med. 2007;100:193–201.CrossRefGoogle Scholar
  9. 9.
    Rizzo C, Ceccarelli F, Gattamelata A, et al. Ultrasound in rheumatoid arthritis. Med Ultrason. 2013;15(3):199–208.PubMedCrossRefGoogle Scholar
  10. 10.
    Quan L, Thiele GM, Tian J, Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat. 2008;18(7):723–38. doi:10.1517/13543776.18.7.723.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39.CrossRefGoogle Scholar
  12. 12.
    Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Arvonen M, Virta LJ, Pokka T, et al. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this groups’ greater susceptibility to infections? J Rheumatol. 2015;42(3):521–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Petty RE, Southwood TR, Manners P, International League of Associations for Rheumatology, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMedGoogle Scholar
  15. 15.
    Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117(5):1843–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, Dewitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.CrossRefGoogle Scholar
  17. 17.
    Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am. 2009;35(1):21–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim PS, Klausmeier TL, Orr DP. Reactive arthritis: a review. J Adolesc Health. 2009;44(4):309–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide. BioDrugs. 2000;13(1):21–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMedCrossRefGoogle Scholar
  21. 21.
    Ainila H, Hietaharju A, Loukkola J. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Care Res. 2001;45(5):419–23.CrossRefGoogle Scholar
  22. 22.
    Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67(2):195–205.PubMedCrossRefGoogle Scholar
  23. 23.
    Hahn BV, McMahon M, Wilkinson A, et al. American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808.CrossRefGoogle Scholar
  24. 24.
    Gayraud M. Raynaud’s phenomenon. Joint Bone Spine. 2007;74(1):e1–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012;8(8):469–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2014;1:CD002069.PubMedGoogle Scholar
  27. 27.
    van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity. 2005;38(2):113–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Hissaria P, Roberts-Thomson PJ, Lester S, Ahern MJ, Smith MD, Walker JG. Cigarette smoking in patients with systemic sclerosis – reduces overall survival. Arthritis Rheum. 2011;63(6):1758–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Gálvez J, Sáiz E, López P, Pina MA, Carrillo A, Nieto A, et al. Diagnostic evaluation and classification criteria in Sjögren’s syndrome. Joint Bone Spine. 2008;76(1):44–49.Google Scholar
  32. 32.
    Thanou-Stavraki A, James JA. Primary Sjogren’s syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37(5):273–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68(2):284–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Caylor TL, Perkins A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. Am Fam Physician. 2013;88(10):676–84.PubMedGoogle Scholar
  35. 35.
    Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatic: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484–92.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Ghosh P, Borg FA, Dasgupta B. Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Expert Rev Clin Immunol. 2010;6(6):913–28.PubMedCrossRefGoogle Scholar
  37. 37.
    Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169(20):1839–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum. 2004;33(5):294–301.PubMedCrossRefGoogle Scholar
  39. 39.
    Waldman CW, Waldman SD, Waldman RA. Giant cell arteritis. Med Clin North Am. 2013;97(2):329–35.PubMedCrossRefGoogle Scholar
  40. 40.
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Dasgupta B. Giant Cell Arteritis Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med. 2010;10(4):381–6.PubMedCrossRefGoogle Scholar
  42. 42.
    van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin N Am. 1998;24(4):663–76.CrossRefGoogle Scholar
  43. 43.
    Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol. 2001;13(4):265–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis. 1973;32(4):354–63.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Goie HS, Steven MM, van der Linden SM, et al. Evaluation of diagnostic criteria for anklyosing spondylitis: a comparison of Rome, New York and modified New York criteria in patients with a positive clinical screening test for ankylosing spondylitis. Br J Rheumatol. 1985;24(3):242–9.CrossRefGoogle Scholar
  46. 46.
    Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol. 2007;18(6):476–80.PubMedCrossRefGoogle Scholar
  48. 48.
    van der Heijde D, Landewé R. Imaging in spondylitis. Curr Opin Rheumatol. 2005;17(4):413–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford). 2010;49(7):1317–25.CrossRefGoogle Scholar
  50. 50.
    Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008;(1):CD002822.Google Scholar
  51. 51.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.PubMedCrossRefGoogle Scholar
  52. 52.
    Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11(1):214.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2015

Authors and Affiliations

  1. 1.Department of Family MedicineUniformed Services University of the Health SciencesBethesdaUSA
  2. 2.Associate Dean for Medical Education, F. Edward Hebert School of MedicineUniformed Services, University of the Health SciencesBethesdaUSA

Personalised recommendations